Ionis Pharmaceuticals Inc

NASDAQ:IONSUnited States

May 16, 2024

Show headlines and story abstract

• Sector Update: Health Care Stocks Mixed in Late Afternoon Trading, from 3:58PM ET on Thursday May 16, 2024 by MT Newswires

  3:58PM ET on Thursday May 16, 2024 by MT Newswires
  Companies Mentioned: IONS, BIIB, CLVR, GLUE, TRUP
  03:58 PM EDT, 05/16/2024 (MT Newswires) -- Health care stocks were mixed late Thursday afternoon, with the NYSE Health Care Index decreasing 0.1% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. The iShares Biotechnology ETF (IBB) was flat...

• Sector Update: Health Care Stocks Ease Thursday Afternoon, from 2:02PM ET on Thursday May 16, 2024 by MT Newswires

  2:02PM ET on Thursday May 16, 2024 by MT Newswires
  Companies Mentioned: IONS, OGEN, BIIB, TRUP
  02:02 PM EDT, 05/16/2024 (MT Newswires) -- Health care stocks were lower Thursday afternoon, with the NYSE Health Care Index decreasing 0.2% and the Health Care Select Sector SPDR Fund (XLV) fractionally lower. The iShares Biotechnology ETF (IBB) wa...

• DJ Ionis to Fly Solo on Angelman Syndrome Drug -- Market Talk, from 11:52AM ET on Thursday May 16, 2024 by Dow Jones

  11:52AM ET on Thursday May 16, 2024 by Dow Jones
  Companies Mentioned: IONS, BIIB
  
  1152 ET - Ionis Pharmaceuticals will advance its ION582 candidate for the genetic disorder Angelman syndrome after partner Biogen elected not to exercise its option to license and lead development of the program. Ionis says ION582 showed consistent improvements across multiple functional domains in a Phase 1/2a study, and that it plans to review the results with regulatory authorities to align on the design of a pivotal trial. Ionis and Biogen, who have worked together since 2012, also said they were pulling the plug on an investigational therapy for amyotrophic lateral sclerosis, the neurodegenerative disorder commonly known as Lou Gehrig's disease, after a study showed it didn't slow the disease process. Ionis down 4.9% to $37.30. (colin.kellaher@wsj.com)